Susquehanna International Group, LLP Atreca, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.78 - $1.68 $43,680 - $94,080	-56,000 Reduced 51.09%	53,600 $42,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $2.74 $153,117 - $263,862	96,300 Added 724.06%	109,600 $172,000
Q2 2022 Aug 15, 2022	BUY	$1.56 - $3.25 $4,524 - $9,425	2,900 Added 27.88%	13,300 $24,000
Q4 2021 Feb 14, 2022	SELL	$2.87 - $6.29 $156,989 - $344,063	-54,700 Reduced 84.02%	10,400 $32,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $66,285 - $122,445	13,500 Added 26.16%	65,100 $406,000
Q2 2021 Aug 11, 2021	BUY	$7.82 - $13.8 $318,274 - $561,660	40,700 Added 373.39%	51,600 $440,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $141,700 - $210,806	10,900 New	10,900 $167,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.